Bristol-Myers upgraded to Overweight with $52 target at JPMorgan JPMorgan upgraded Bristol-Myers to Overweight from Neutral citing the recent pullback in shares and immunotherapy pipeline catalysts over the next 12-18 months. The firm raised its price target for the name to $52 from $50.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Vertex, Regeneron speculated to be merger targets, TheStreet says Among the predictions for the biotech sector in 2014 made by David Sobek of TheStreet.com was a call for "at least two" mergers between large-cap companies. Sobek predict Sanofi (SNY) will buy Regeneron (REGN) and that Bristol-Myers Squibb (BMY) will acquire Vertex Pharmaceuticals (VRTX). Reference Link